Summary of Cidara Therapeutics (CDTX) Core Viewpoint - Cidara Therapeutics (CDTX) shows potential for significant upside, with a mean price target of 23.10 [1]. Price Target Analysis - The average price target consists of six estimates ranging from 46, with a standard deviation of $5.87, suggesting a consensus among analysts [2]. - The lowest estimate indicates a 42.9% increase, while the highest suggests a 99.1% upside [2]. - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [7]. Earnings Estimates and Analyst Sentiment - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [9]. - The Zacks Consensus Estimate for the current year has risen by 50.5% over the past month, with no negative revisions [10]. - CDTX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [11]. Caution on Price Targets - While price targets are a common tool for investors, they can often mislead, and reliance solely on them may not yield favorable returns [5][8]. - Analysts may set optimistic price targets due to business incentives, which can inflate expectations [6].
Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know